REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX) is a biotechnology company specializing in the development and commercialization of gene therapy treatments. Founded in 2013, it focuses on leveraging its proprietary NAV Technology platform to create novel therapeutic options for a range of genetic, neurovascular, and retinal diseases. The company's goal is to advance gene therapy science and deliver transformative treatments to patients.
Company News
The global viral vector gene therapy market is projected to grow from $13.14 billion in 2024 to $38.39 billion by 2034, driven by advancements in vector design, increasing genetic disease prevalence, and strong R&D investments.
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space. Oppenheimer writes, “We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therap...
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The threat is still emerging, but it could be significant.